SLXP

Salix Pharmaceuticals, Ltd. Press Releases

$141.99
*  
1.99
1.42%
Get SLXP Alerts
*Delayed - data as of Oct. 20, 2014  -  Find a broker to begin trading SLXP now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By
Salix Pharmaceuticals Outlines Data Presentations at American College of Gastroenterology 2014 Annual Scientific Meeting
10/17/2014 7:00:00 AM - Business Wire
▲2.98 % Price Change since this news event. The Volume Ratio is 1.37.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


FDA Approves UCERIS® (Budesonide) 2mg Rectal Foam for the Induction of Remission of Mild-to-Moderate Distal Ulcerative Colitis
10/8/2014 8:30:00 AM - Business Wire


Northisle Announces Step-Out Hole Intersects Copper Mineralization 700 Metres Northwest of Hushamu Deposit
10/8/2014 8:30:00 AM - Market Wire


Progenics Receives $40 Million Milestone Following FDA Approval of RELISTOR for OIC Patients With Chronic Non-Cancer Pain
10/6/2014 4:31:00 PM - GlobeNewswire


Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP) to Ring The Nasdaq Stock Market Closing Bell
10/3/2014 10:00:00 AM - GlobeNewswire


Salix Pharmaceuticals and Cosmo Technologies Announce Termination of Merger Agreement
10/3/2014 12:01:00 AM - Business Wire


FDA Approves RELISTOR® Subcutaneous Injection for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-cancer Pain
9/29/2014 5:30:00 PM - Business Wire


Pentwater Capital Management Issues Letter to Board of Directors of Allergan, Inc.
9/25/2014 10:03:00 PM - PR Newswire


Salix Announces FDA User Fee Goal Date of February 28, 2015 for XIFAXAN® 550mg sNDA for Treatment of Irritable Bowel Syndrome with Diarrhea
9/18/2014 1:42:00 PM - Business Wire


Salix Secures Additional Intellectual Property Relating to Rifaximin
9/18/2014 7:30:00 AM - Business Wire


UCERIS® (budesonide) 2mg Rectal Foam for the Induction of Remission of Mild-to-Moderate Distal Ulcerative Colitis Granted Tentative Approval by FDA
9/15/2014 5:31:00 PM - Business Wire


Salix Submits Response to XIFAXAN® 550mg Complete Response Letter Regarding Repeat Treatment for Irritable Bowel Syndrome with Diarrhea
9/2/2014 7:19:00 AM - Business Wire


Salix Announces Early Termination of HSR Waiting Period for Pending Transaction
8/19/2014 7:00:00 AM - Business Wire


Salix Announces Important Topline Results for Microbiome, Culture & Susceptibility, and Key Secondary Efficacy Results for TARGET 3, Rifaximin IBS-D Repeat Treatment Study
8/11/2014 2:01:00 PM - Business Wire


FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal Date for RELISTOR® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain
8/11/2014 7:00:00 AM - Business Wire


Salix Pharmaceuticals Reports 2Q2014 Results
8/7/2014 4:01:00 PM - Business Wire


INVESTOR ALERT – Salix Pharmaceuticals, Ltd.: The Law Offices of Vincent Wong Investigates the Sale of Salix Pharmaceuticals, Ltd. to Cosmo Pharmaceuticals S.p.A
8/1/2014 2:25:00 PM - Business Wire


Lifshitz & Miller Law Firm Announces Investigation of Design Within Reach, Inc., Family Dollar Stores, Inc., GFI Group Inc., Intermountain Community Bancorp, Rockwood Holdings, Inc., and Salix Pharmaceuticals Ltd.
7/31/2014 1:19:00 PM - PR Newswire


INVESTOR ALERT - Salix Pharmaceuticals, Ltd.: The Law Offices of Vincent Wong Investigates the Sale of Salix Pharmaceuticals, Ltd. - SLXP
7/28/2014 5:40:00 PM - PR Newswire


Salix Pharmaceuticals Announces 2Q2014 Financial Results Conference Call and Webcast
7/24/2014 7:00:00 AM - Business Wire